StockTipsArenaBeta

BUY Zydus Lifesciences Limited — Siddharth Rai Mangala

BUYZydus Lifesciences Limited
Zydus Lifesciences share price target & all analyst calls

bySiddharth Rai MangalaHorizon: NA (inferred Swing (≤2wk))15 Oct 2026via Zee Business (Live)

Entry₹1,143.5Inferred
Target₹1,165
Total upside +1.88%
Stop loss₹1,135-0.74% risk
CMP₹1,140.24h ago
Active-0.29%+2.18%upside left 14d left
Follow Siddharth Rai Mangala for new calls(30% target hit, 169 closed calls)Get alertsWatch ZYDUSLIFE for new buy/sell callsGet alertsSee 223 other Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 15 Oct, 8:16 pm IST
5 supporting4 opposing
Supports the BUY call (5)

Zydus Sunshine Lifesciences has signed an agreement with the Sri Lankan Board of Investment to set up a pharmaceutical manufacturing facility.

BSE · Company Update·15 Oct · today

(opens in new tab)

The US FDA has accepted the review for FYB206, a Keytruda biosimilar developed by Zydus and Formycon.

BSE · Company Update·13 Oct · 2d ago

(opens in new tab)

The USFDA has accepted for review the company's biosimilar candidate FYB206, a Keytruda biosimilar developed in partnership with Formycon.

NSE · Press Release·13 Oct · 2d ago

(opens in new tab)

Zydus presented Phase 3 trial data showing improved biochemical response for Saroglitazar compared to placebo.

BSE · Company Update·12 Oct · 3d ago

(opens in new tab)

Zydus Lifesciences and MSN have partnered to launch the first generic version of Adempas (Riociguat tablets) in the U.S. market.

BSE · Company Update·5 Oct · 1w ago

(opens in new tab)
Neutral / worth noting (0)

Nothing found in this tip’s window yet.

Weighs against the BUY call (4)

MACD below its signal line — bearish momentum

Technicals · macd·15 Oct · today

Zydus Lifesciences' USFDA inspection at Ahmedabad plant concludes with 5 observations

NewsCnbc-Tv18·13 Oct · yesterday

(opens in new tab)

The USFDA concluded an inspection of Zydus Lifesciences' Moraiya manufacturing plant with 5 observations, which the company intends to address.

NSE · Press Release·13 Oct · yesterday

(opens in new tab)

The USFDA concluded an inspection of the company's Moraiya manufacturing plant with 5 observations.

BSE · Company Update·13 Oct · yesterday

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Zydus Lifesciences

All analyst calls on Zydus Lifesciences

More from Siddharth Rai Mangala

Every call and its outcome